Program (subject to change)

8:00-8:30 AM  Registration and Continental Breakfast

8:30-8:40 AM  Welcome/Introduction
               Jason Gotlib, MD, MS

8:40-9:15 AM  Myelodysplastic Syndromes (MDS)
               Peter Greenberg, MD

9:15-9:50 AM  Acute Myeloid Leukemia (AML)
               Bruno Medeiros, MD

9:50-10:05 AM Q&A Session
               Peter Greenberg, MD and Bruno Medeiros, MD

10:05-10:20 AM Break

10:20-11:30 AM Non-Malignant Hematology Case-Based Panel Discussion
               Caroline Berube, MD; Lawrence Leung, MD; Stanley Schrier, MD; Moderator: Michaela Liedtke, MD

11:30-12:30 PM Lunch

12:30-1:30 PM  Molecular Hematopathology Tumor Board
               Dita Gratzinger, MD, PhD; Robert Ohgami, MD, PhD; James Zehnder, MD

1:35-2:10 PM  Multiple Myeloma (MM)
               Michaela Liedtke, MD

2:10-2:45 PM  Myeloproliferative Neoplasms (MPN)
               Jason Gotlib, MD, MS

2:45-3:00 PM  Q&A Session
               Michaela Liedtke, MD and Jason Gotlib, MD, MS

3:00-3:15 PM  Break

3:15-3:50 PM  Chronic Lymphocytic Leukemia (CLL)
               Steven Coutre, MD

3:50-4:30 PM  Hodgkin and Non-Hodgkin Lymphomas
               Ranjana Advani, MD

4:30-4:45 PM  Q&A Session
               Steven Coutre, MD and Ranjana Advani, MD

4:45-4:50 PM  Closing Remarks

February 3, 2018
8:00 AM - 4:50 PM
Ritz-Carlton
Half Moon Bay, CA

Stanford's Review of the 59th Annual American Society of Hematology Meeting 2018
A Continuing Medical Education Conference Presented by the Division of Hematology at the Stanford University School of Medicine

Sponsored by the Stanford University School of Medicine

Faculty

All faculty are with the Stanford University School of Medicine unless otherwise noted.

Course Director
Jason Gotlib, MD, MS
Professor of Medicine, Division of Hematology

Course Co-Director
Michaela Liedtke, MD
Associate Professor of Medicine, Division of Hematology

Stanford Faculty
Ranjana Advani, MD
Saul A. Rosenberg MD, Professor of Lymphoma
Division of Hematology

Caroline Berube, MD
Clinical Associate Professor, Division of Hematology

Steven Coutre, MD
Professor of Medicine, Division of Hematology

Dita Gratzinger, MD, PhD
Assistant Professor of Pathology, Department of Pathology

Peter Greenberg, MD
Professor of Medicine, Emeritus, Division of Hematology

Lawrence Leung, MD
Professor of Medicine, Division of Hematology

Bruno Medeiros, MD
Associate Professor of Medicine, Division of Hematology

Robert Ohgami, MD, PhD
Assistant Professor, Department of Pathology

Stanley Schrier, MD
Professor of Medicine, Emeritus, Division of Hematology

James Zehnder, MD
Professor, Department of Medicine (Hematology) and Department of Pathology

Faculty Disclosure
The Stanford University School of Medicine adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education. Disclosure of faculty and their commercial relationships will be made prior to the activity.

Register online at cme.stanford.edu/hematology
STATEMENT OF NEED
This CME event led by the Stanford Division of Hematology seeks to fulfill the need of practicing Hematologists/Oncologists, Nurse Practitioners, Physician Assistants, Pharmacists and Allied Health Care Practitioners in the academic and community settings to increase the fund of knowledge in malignant and benign hematologic disorders by reviewing the latest data presented at the 59th Annual American Society of Hematology Meeting. The goal of the symposium is to enhance both competence and performance of practitioners in the diagnosis, prognostication, and treatment of patients with malignant and non-malignant hematologic disorders.

TARGET AUDIENCE
This conference is for hematologists, oncologists, nurse practitioners, physician assistants, nurses and pharmacists who care for patients with malignant and benign hematologic diseases.

LEARNING OBJECTIVES
At the conclusion of this activity, learners will be able to:

Review and evaluate data from the most recent clinical trials and develop strategies to:

1. Evaluate new chemotherapy/biologic regimens for different subpopulations of acute myeloid leukemia patients based on clinical and genetic prognostic factors and determine how to apply them to treatment decisions.
2. Apply strategies to optimally utilize JAK inhibition and other novel agents in patients with myelofibrosis, polycythemia vera (PV), and other relevant Myeloproliferative Neoplasms (MPNs) and use prognostic models to risk stratify MPN patients for therapy.
3. Analyze the role of new biologics for advanced systemic mastocytosis.
4. Evaluate optimal sequencing and combinations of novel biologics for Chronic Lymphocytic Leukemia (CLL), and the current role of testing for molecular abnormalities and Minimal Residue Disease (MRD) testing.
5. Incorporate available therapeutic options for patients with low- or high-risk myelodysplastic syndromes, including those who are relapsed/refractory to hypomethylating agents and utilize the IPSS-R prognostic scoring system and new mutation data to classify patients for treatment.
6. Determine the best combination regimens and novel agents for relevant populations of newly diagnosed and relapsed/refractory myeloma patients, including transplant eligible vs. ineligible, and new antibody therapies, as well as the role for MRD testing.
7. Evaluate the results of phase II/III trials in Hodgkin and non-Hodgkin lymphomas.
8. Determine appropriate use of emerging novel therapies for patients with hemophilia.
10. Review new therapeutic directions in sickle cell disease and disorders of iron homeostasis.

ACCREDITATION
The Stanford University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
The Stanford University School of Medicine designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CANCELLATION POLICY
Cancellations received in writing no less than 30 days before the course will be refunded, less a 20% administrative fee. No refunds will be made on cancellations received after that date. Please send cancellation requests to stanfordcme@stanford.edu.

CONFERENCE LOCATION
Ritz-Carlton
1 Miramontes Point Rd, Half Moon Bay, CA 94019
(650) 712-7000
www.ritzcarlton.com/en/hotels/california/half-moon-bay

LODGING & DIRECTIONS
For reservations, call (800) 241-3333 before January 2, 2018 and reference the name of the event.

VISITOR INFORMATION
For more information about Half Moon Bay, CA please visit www.visithalfmoonbay.org.

CONTACT INFORMATION
For questions about the symposium, please contact Dianna Ziehm, CME Conference Coordinator, (650) 724-7166 or email dziemh@stanford.edu.

Stanford Center for Continuing Medical Education
1520 Page Mill Road, Palo Alto, CA 94304
Phone: (650) 497-8554 • Email: stanfordcme@stanford.edu • Web: cme.stanford.edu

Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. If you have needs that require special accommodations, including dietary concerns, please contact the CME Conference Coordinator.